Covered recipient · General Payments record
JOHN RUBINO
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$410.97
28 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $410.97 | 28 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $75.09 | 5 |
| Esperion Therapeutics, Inc. | $48.35 | 3 |
| AstraZeneca Pharmaceuticals LP | $47.40 | 3 |
| Merck Sharp & Dohme Corporation | $40.22 | 3 |
| AbbVie Inc. | $36.26 | 2 |
| Amarin Pharma Inc. | $30.53 | 2 |
| Novo Nordisk Inc | $28.86 | 2 |
| GlaxoSmithKline, LLC. | $23.60 | 2 |
| Lilly USA, LLC | $19.59 | 1 |
| Eisai Inc. | $19.41 | 1 |
| Allergan, Inc. | $17.73 | 1 |
| Daiichi Sankyo Inc. | $17.00 | 1 |
| PFIZER INC. | $6.93 | 2 |
Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JOHN RUBINO
NPI 1962543280 · CMS profile ID 43312
Allopathic & Osteopathic Physicians / Internal Medicine
RALEIGH, NC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1962543280?year=2020&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JOHN RUBINO, NPI 1962543280, CMS profile ID 43312. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962543280?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). JOHN RUBINO, NPI 1962543280, CMS profile ID 43312. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962543280?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- JOHN RUBINO, NPI 1962543280, CMS profile ID 43312, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–28 of 28 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1962543280?year=2020&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
28 matching records · $410.97 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–28 of 28.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | $12.86 | 12/16/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741144097 | CMS |
| Esperion Therapeutics, Inc. | $19.64 | 11/18/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 737238449 | CMS |
| Amgen Inc. | $15.10 | 11/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741144103 | CMS |
| Lilly USA, LLC | $19.59 | 11/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728484903 | CMS |
| Amgen Inc. | $13.38 | 10/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741144095 | CMS |
| Esperion Therapeutics, Inc. | $14.17 | 10/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 737238445 | CMS |
| Merck Sharp & Dohme Corporation | $15.17 | 10/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747793855 | CMS |
| Amgen Inc. | $18.88 | 09/30/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741144101 | CMS |
| Esperion Therapeutics, Inc. | $14.54 | 09/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 737238441 | CMS |
| GlaxoSmithKline, LLC. | $11.50 | 09/09/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738494879 | CMS |
| Amarin Pharma Inc. | $14.09 | 09/02/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739927757 | CMS |
| Merck Sharp & Dohme Corporation | $14.15 | 08/19/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747700975 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.71 | 08/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736122563 | CMS |
| Eisai Inc. | $19.41 | 07/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751216017 | CMS |
| Novo Nordisk Inc | $15.90 | 07/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744799765 | CMS |
| GlaxoSmithKline, LLC. | $12.10 | 07/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738882961 | CMS |
| Amarin Pharma Inc. | $16.44 | 07/08/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 740047055 | CMS |
| AstraZeneca Pharmaceuticals LP | $12.31 | 06/17/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 735757287 | CMS |
| AstraZeneca Pharmaceuticals LP | $12.38 | 06/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736172137 | CMS |
| Amgen Inc. | $14.87 | 03/25/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741144091 | CMS |
| PFIZER INC. | $1.79 | 03/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743524571 | CMS |
| PFIZER INC. | $5.14 | 03/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743578179 | CMS |
| AbbVie Inc. | $23.57 | 02/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 722103655 | CMS |
| AbbVie Inc. | $12.69 | 02/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 722103653 | CMS |
| Allergan, Inc. | $17.73 | 02/05/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723437311 | CMS |
| Daiichi Sankyo Inc. | $17.00 | 01/29/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739479341 | CMS |
| Novo Nordisk Inc | $12.96 | 01/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744573331 | CMS |
| Merck Sharp & Dohme Corporation | $10.90 | 01/08/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747736625 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,783,192.12 | 359 |
| PY2024 | Recipient | $66,231.01 | 15 |
| PY2024 | Principal investigator | $2,510,578.54 | 317 |
| PY2023 | Recipient | $6,417.61 | 4 |
| PY2023 | Principal investigator | $2,159,960.11 | 267 |
| PY2022 | Principal investigator | $2,441,546.83 | 286 |
| PY2021 | Principal investigator | $1,166,336.49 | 169 |
| PY2020 | Principal investigator | $1,326,147.90 | 192 |
| PY2019 | Principal investigator | $636,986.48 | 193 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
359 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $600.00 | 12/31/2025 | Non-covered Recipient Entity PMG RESEARCH INC | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension | No dispute reported | 06/30/2026 | 1202532318 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 12/23/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192168244 |
| Principal investigator 1 | BioNTech SE | $2,148.00 | 12/19/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021721 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $14,143.00 | 12/19/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211569392 |
| Principal investigator 1 | ModernaTX, Inc. | $51,816.50 | 12/19/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991894 |
| Principal investigator 1 | ModernaTX, Inc. | $8,325.75 | 12/19/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991906 |
| Principal investigator 1 | ModernaTX, Inc. | $832.02 | 12/19/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991938 |
| Principal investigator 1 | ModernaTX, Inc. | $4,237.80 | 12/19/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991970 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,506.95 | 12/19/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184278890 |
| Principal investigator 1 | PFIZER INC. | $702.00 | 12/15/2025 | Non-covered Recipient Entity Accellacare Raleigh | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228806697 |
| Principal investigator 1 | PFIZER INC. | $702.00 | 12/15/2025 | Non-covered Recipient Entity Accellacare Raleigh | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228806781 |
| Principal investigator 1 | PFIZER INC. | $13,500.00 | 12/12/2025 | Non-covered Recipient Entity Accellacare US Inc | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228806692 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $114.00 | 12/11/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184274444 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $376.65 | 12/11/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184274450 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,626.75 | 12/11/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184274452 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,050.00 | 12/11/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184274454 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,108.10 | 12/11/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184274783 |
| Principal investigator 1 | ABBVIE INC. | $5,869.80 | 12/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202528064 |
| Principal investigator 1 | BioNTech SE | $2,507.00 | 12/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021697 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,806.00 | 12/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192168239 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $61.00 | 12/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211569334 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $500.00 | 12/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211569446 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $9,186.00 | 12/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211569494 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,601.15 | 12/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184269175 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 12/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184269263 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,072.25 | 12/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184269373 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,774.25 | 12/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184269381 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $216.00 | 12/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184269385 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $114.00 | 12/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184269391 |
| Principal investigator 1 | ModernaTX, Inc. | $16,581.28 | 11/27/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991884 |
| Principal investigator 1 | ModernaTX, Inc. | $832.02 | 11/27/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991886 |
| Principal investigator 1 | ModernaTX, Inc. | $9,888.20 | 11/27/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991960 |
| Principal investigator 1 | ModernaTX, Inc. | $8,815.50 | 11/27/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252992002 |
| Principal investigator 1 | ABBVIE INC. | $1,397.75 | 11/26/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202525548 |
| Principal investigator 1 | BioNTech SE | $4,655.00 | 11/25/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021723 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,493.50 | 11/25/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184264469 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/24/2025 | Non-covered Recipient Entity Accellacare Raleigh | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228808864 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/24/2025 | Non-covered Recipient Entity Accellacare Raleigh | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228808870 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/24/2025 | Non-covered Recipient Entity Accellacare Raleigh | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228808876 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/24/2025 | Non-covered Recipient Entity Accellacare Raleigh | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228808958 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/24/2025 | Non-covered Recipient Entity Accellacare Raleigh | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228808964 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/24/2025 | Non-covered Recipient Entity Accellacare Raleigh | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228809191 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/24/2025 | Non-covered Recipient Entity Accellacare Raleigh | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228809273 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/24/2025 | Non-covered Recipient Entity Accellacare Raleigh | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228809278 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/24/2025 | Non-covered Recipient Entity Accellacare Raleigh | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228809285 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 11/24/2025 | Non-covered Recipient Entity Accellacare Raleigh | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228809341 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $32,407.00 | 11/20/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211569126 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,225.47 | 11/20/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184263537 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 11/20/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184263571 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $153.90 | 11/20/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184263573 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,774.25 | 11/20/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184263575 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,708.15 | 11/20/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184263577 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $684.00 | 11/20/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184263579 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 11/20/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184263589 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $13.74 | 11/15/2025 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190308046 |
| Principal investigator 1 | BioNTech SE | $12,251.00 | 11/14/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021717 |
| Principal investigator 1 | BioNTech SE | $138.42 | 11/14/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249022054 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $50,666.00 | 11/14/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211568990 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $724.00 | 11/14/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211569134 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $203.00 | 11/14/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211569168 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $105.00 | 11/14/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211569207 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $4,965.00 | 11/14/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211569285 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,246.75 | 11/14/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184261261 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $392.04 | 11/14/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184261275 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $19,602.00 | 11/14/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184261277 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,132.00 | 11/14/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184261279 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,623.75 | 11/14/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184261281 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10,172.25 | 11/14/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184261283 |
| Principal investigator 1 | PFIZER INC. | $180.80 | 11/12/2025 | Non-covered Recipient Entity Accellacare Raleigh | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228806786 |
| Principal investigator 1 | PFIZER INC. | $265.20 | 11/12/2025 | Non-covered Recipient Entity Accellacare Raleigh | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228806791 |
| Principal investigator 1 | BioNTech SE | $1,386.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021699 |
| Principal investigator 1 | BioNTech SE | $5,211.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021701 |
| Principal investigator 1 | BioNTech SE | $2,772.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021703 |
| Principal investigator 1 | BioNTech SE | $9,330.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021705 |
| Principal investigator 1 | BioNTech SE | $8,012.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021707 |
| Principal investigator 1 | BioNTech SE | $17,114.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021709 |
| Principal investigator 1 | BioNTech SE | $5,014.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021711 |
| Principal investigator 1 | BioNTech SE | $2,704.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021713 |
| Principal investigator 1 | BioNTech SE | $2,704.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021715 |
| Principal investigator 1 | BioNTech SE | $183.58 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021725 |
| Principal investigator 1 | BioNTech SE | $183.58 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021727 |
| Principal investigator 1 | BioNTech SE | $300.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021733 |
| Principal investigator 1 | BioNTech SE | $700.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021735 |
| Principal investigator 1 | BioNTech SE | $192.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021737 |
| Principal investigator 1 | BioNTech SE | $90.42 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021739 |
| Principal investigator 1 | BioNTech SE | $300.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021743 |
| Principal investigator 1 | BioNTech SE | $300.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021745 |
| Principal investigator 1 | BioNTech SE | $300.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021747 |
| Principal investigator 1 | BioNTech SE | $300.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021749 |
| Principal investigator 1 | BioNTech SE | $176.73 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249022025 |
| Principal investigator 1 | BioNTech SE | $90.42 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249022049 |
| Principal investigator 1 | BioNTech SE | $542.84 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249022063 |
| Principal investigator 1 | BioNTech SE | $131.52 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249022077 |
| Principal investigator 1 | H. Lundbeck A S | $2,000.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251776593 |
| Principal investigator 1 | H. Lundbeck A S | $1,500.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251776606 |
| Principal investigator 1 | H. Lundbeck A S | $350.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251776718 |
| Principal investigator 1 | H. Lundbeck A S | $750.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251776756 |
| Principal investigator 1 | H. Lundbeck A S | $1,300.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251776760 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $31,464.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | No dispute reported | 06/30/2026 | 1211569240 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,905.07 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184257849 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,653.50 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184257927 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,425.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184257977 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10,172.25 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184257999 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $392.04 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258021 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,623.75 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258043 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $22,734.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258047 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $171.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258213 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $324.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258215 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,402.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258307 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $14,175.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258309 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,473.25 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258311 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $684.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258313 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $196.02 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258315 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,392.48 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258317 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $321.30 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258349 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258359 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $972.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258361 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $513.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258363 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $963.90 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258365 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $399.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258383 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,077.30 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258385 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258387 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258425 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $513.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258453 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,474.90 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258455 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $165.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258457 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10,125.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258459 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $897.48 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258557 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $14,175.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258559 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,922.02 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258561 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $855.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258563 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,473.25 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258565 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $648.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258605 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258607 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,214.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258609 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $342.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258611 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,821.50 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258693 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $171.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258695 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $805.95 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258697 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,774.25 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258699 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258711 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,849.50 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258723 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $114.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258725 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258727 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $537.30 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258729 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258763 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,600.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258787 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $495.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258819 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258821 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $924.75 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258831 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,119.50 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258833 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $171.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258835 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $324.00 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258837 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,792.07 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258905 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,532.84 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258949 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10,720.90 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184259071 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $23,312.88 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184259137 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $20,540.25 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184259185 |
| Principal investigator 1 | TOLMAR, INC. | $3,179.25 | 11/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | TOL-CLAR-20024 | No dispute reported | 06/30/2026 | 1237323304 |
| Principal investigator 1 | ABBVIE INC. | $44.55 | 11/06/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202523355 |
| Principal investigator 1 | ABBVIE INC. | $318.60 | 11/06/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202523369 |
| Principal investigator 1 | ABBVIE INC. | $3,205.91 | 11/05/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202522287 |
| Principal investigator 1 | BioNTech SE | $155.68 | 11/05/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249022059 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $223.00 | 11/03/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192168226 |
| Principal investigator 1 | ModernaTX, Inc. | $2,496.06 | 10/27/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991898 |
| Principal investigator 1 | ModernaTX, Inc. | $5,297.25 | 10/27/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991948 |
| Principal investigator 1 | ModernaTX, Inc. | $9,128.94 | 10/27/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991958 |
| Principal investigator 1 | Amgen Inc. | $81,876.55 | 10/24/2025 | Non-covered Recipient Entity ACELLACARE US INC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | No dispute reported | 06/30/2026 | 1246638823 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,077.30 | 10/17/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192168391 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $192,292.65 | 10/16/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184250581 |
| Principal investigator 1 | BioNTech SE | $58.00 | 10/15/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021719 |
| Principal investigator 1 | ABBVIE INC. | $17,926.31 | 10/09/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202516119 |
| Principal investigator 1 | BioNTech SE | $70.99 | 10/02/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249022045 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,862.95 | 10/02/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192168223 |
| Principal investigator 1 | ABBVIE INC. | $815.40 | 09/30/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202512874 |
| Principal investigator 1 | ABBVIE INC. | $89.10 | 09/30/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202512876 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 09/30/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202512878 |
| Principal investigator 1 | ModernaTX, Inc. | $832.02 | 09/29/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991914 |
| Principal investigator 1 | ModernaTX, Inc. | $15,538.60 | 09/29/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991934 |
| Principal investigator 1 | ModernaTX, Inc. | $4,339.88 | 09/29/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991972 |
| Principal investigator 1 | ModernaTX, Inc. | $8,521.65 | 09/29/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991990 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $196.00 | 09/08/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192168235 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $294.00 | 09/05/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192165108 |
| Principal investigator 1 | ABBVIE INC. | $4,145.85 | 09/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202509858 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,905.07 | 09/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184235213 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,048.20 | 09/03/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192165112 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 08/28/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202506405 |
| Principal investigator 1 | ABBVIE INC. | $579.15 | 08/28/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202506433 |
| Principal investigator 1 | ABBVIE INC. | $764.10 | 08/28/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202506435 |
| Principal investigator 1 | ModernaTX, Inc. | $14,104.61 | 08/28/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991888 |
| Principal investigator 1 | ModernaTX, Inc. | $10,167.21 | 08/28/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991910 |
| Principal investigator 1 | ModernaTX, Inc. | $4,237.80 | 08/28/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991986 |
| Principal investigator 1 | H. Lundbeck A S | $350.00 | 08/21/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251773792 |
| Principal investigator 1 | H. Lundbeck A S | $350.00 | 08/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251773287 |
| Principal investigator 1 | ABBVIE INC. | $8,074.35 | 08/06/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202503097 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,000.00 | 08/06/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192168215 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,986.30 | 08/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192168219 |
| Principal investigator 1 | ABBVIE INC. | $44.55 | 07/31/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202500558 |
| Principal investigator 1 | ModernaTX, Inc. | $638.40 | 07/31/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991988 |
| Principal investigator 1 | ABBVIE INC. | $1,031.40 | 07/30/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202500428 |
| Principal investigator 1 | ABBVIE INC. | $601.34 | 07/30/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202500438 |
| Principal investigator 1 | ModernaTX, Inc. | $2,118.90 | 07/28/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991896 |
| Principal investigator 1 | ModernaTX, Inc. | $15,189.58 | 07/28/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991946 |
| Principal investigator 1 | ModernaTX, Inc. | $2,389.98 | 07/28/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991964 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $853.10 | 07/23/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192168230 |
| Principal investigator 1 | ABBVIE INC. | $753.35 | 07/10/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202497760 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 07/10/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202497762 |
| Principal investigator 1 | ABBVIE INC. | $311.85 | 07/10/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202497764 |
| Principal investigator 1 | ABBVIE INC. | $106.00 | 07/10/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202497778 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,067.39 | 07/10/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184214456 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 07/10/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184214466 |
| Principal investigator 1 | ABBVIE INC. | $5,952.15 | 07/02/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202493993 |
| Principal investigator 1 | ModernaTX, Inc. | $21,699.40 | 06/27/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991950 |
| Principal investigator 1 | ModernaTX, Inc. | $8,475.60 | 06/27/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991954 |
| Principal investigator 1 | ModernaTX, Inc. | $7,130.76 | 06/27/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252992006 |
| Principal investigator 1 | BioNTech SE | $7,319.00 | 06/24/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249022090 |
| Principal investigator 1 | BioNTech SE | $300.00 | 06/19/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021877 |
| Principal investigator 1 | BioNTech SE | $1,500.00 | 06/19/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021881 |
| Principal investigator 1 | BioNTech SE | $97.27 | 06/19/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021960 |
| Principal investigator 1 | BioNTech SE | $205.50 | 06/19/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021964 |
| Principal investigator 1 | BioNTech SE | $192.00 | 06/19/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021968 |
| Principal investigator 1 | BioNTech SE | $600.00 | 06/19/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021973 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,525.20 | 06/19/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184209382 |
| Principal investigator 1 | ModernaTX, Inc. | $18,716.95 | 06/18/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991966 |
| Principal investigator 1 | ModernaTX, Inc. | $8,933.04 | 06/18/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991968 |
| Principal investigator 1 | ModernaTX, Inc. | $66,183.17 | 06/18/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991974 |
| Principal investigator 1 | BioNTech SE | $93.00 | 06/12/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021832 |
| Principal investigator 1 | BioNTech SE | $144.00 | 06/12/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249022012 |
| Principal investigator 1 | BioNTech SE | $264.00 | 06/12/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249022015 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,067.39 | 06/12/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184206511 |
| Principal investigator 1 | TOLMAR, INC. | $2,188.35 | 06/12/2025 | Non-covered Recipient Entity ACCELLACARE US INC | TOL-CLAR-20024 | No dispute reported | 06/30/2026 | 1237323238 |
| Principal investigator 1 | Amgen Inc. | $17,782.90 | 06/08/2025 | Non-covered Recipient Entity ACCELLACARE OF RALEIGH | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | No dispute reported | 06/30/2026 | 1246638704 |
| Principal investigator 1 | ABBVIE INC. | $133.65 | 06/05/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202490383 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 06/05/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202490385 |
| Principal investigator 1 | H. Lundbeck A S | $350.00 | 06/05/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251770805 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,510.95 | 06/05/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184204261 |
| Principal investigator 1 | TOLMAR, INC. | $1,580.00 | 06/05/2025 | Non-covered Recipient Entity ACCELLACARE US INC | TOL-CLAR-20024 | No dispute reported | 06/30/2026 | 1237323226 |
| Principal investigator 1 | ModernaTX, Inc. | $330.00 | 06/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991882 |
| Principal investigator 1 | ModernaTX, Inc. | $3,321.28 | 06/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991996 |
| Principal investigator 1 | ABBVIE INC. | $7,762.50 | 06/03/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202487979 |
| Principal investigator 1 | ModernaTX, Inc. | $9,501.15 | 05/28/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991904 |
| Principal investigator 1 | ModernaTX, Inc. | $39,199.65 | 05/28/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991916 |
| Principal investigator 1 | ModernaTX, Inc. | $832.02 | 05/28/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991920 |
| Principal investigator 1 | ModernaTX, Inc. | $6,509.82 | 05/28/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991994 |
| Principal investigator 1 | TOLMAR, INC. | $11,381.85 | 05/22/2025 | Non-covered Recipient Entity ACCELLACARE US INC | TOL-CLAR-20024 | No dispute reported | 06/30/2026 | 1237323216 |
| Principal investigator 1 | TOLMAR, INC. | $3,075.30 | 05/22/2025 | Non-covered Recipient Entity ACCELLACARE US INC | TOL-CLAR-20024 | No dispute reported | 06/30/2026 | 1237323219 |
| Principal investigator 1 | TOLMAR, INC. | $81.00 | 05/22/2025 | Non-covered Recipient Entity ACCELLACARE US INC | TOL-CLAR-20024 | No dispute reported | 06/30/2026 | 1237323223 |
| Principal investigator 1 | BioNTech SE | $693.00 | 05/15/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021819 |
| Principal investigator 1 | BioNTech SE | $234.00 | 05/15/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021865 |
| Principal investigator 1 | BioNTech SE | $300.00 | 05/15/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021874 |
| Principal investigator 1 | BioNTech SE | $144.00 | 05/15/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249022001 |
| Principal investigator 1 | BioNTech SE | $47.95 | 05/15/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249022005 |
| Principal investigator 1 | BioNTech SE | $693.00 | 05/15/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249022087 |
| Principal investigator 1 | H. Lundbeck A S | $350.00 | 05/15/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251770281 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,457.81 | 05/15/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184194937 |
| Principal investigator 1 | PFIZER INC. | $75.00 | 05/08/2025 | Non-covered Recipient Entity Accellacare Us Inc | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1228833417 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,641.19 | 05/08/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184193805 |
| Principal investigator 1 | ABBVIE INC. | $7,524.56 | 05/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202483685 |
| Principal investigator 1 | ModernaTX, Inc. | $830.32 | 05/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991928 |
| Principal investigator 1 | ABBVIE INC. | $44.55 | 05/06/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202482019 |
| Principal investigator 1 | BioNTech SE | $8,523.18 | 04/28/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021815 |
| Principal investigator 1 | ModernaTX, Inc. | $1,664.04 | 04/28/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991902 |
| Principal investigator 1 | ModernaTX, Inc. | $8,600.01 | 04/28/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991912 |
| Principal investigator 1 | ModernaTX, Inc. | $1,070.82 | 04/28/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991918 |
| Principal investigator 1 | ModernaTX, Inc. | $44,496.90 | 04/28/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991982 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $17,949.61 | 04/28/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184190781 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,427.46 | 04/23/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184189087 |
| Principal investigator 1 | BioNTech SE | $600.00 | 04/22/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021853 |
| Principal investigator 1 | BioNTech SE | $302.77 | 04/22/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021857 |
| Principal investigator 1 | BioNTech SE | $600.00 | 04/22/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249022093 |
| Principal investigator 1 | BioNTech SE | $600.00 | 04/22/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249022098 |
| Principal investigator 1 | ModernaTX, Inc. | $13,285.12 | 04/16/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991956 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,213.73 | 04/15/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184183428 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,427.46 | 04/08/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184182084 |
| Principal investigator 1 | ABBVIE INC. | $18,522.00 | 04/03/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202470728 |
| Principal investigator 1 | H. Lundbeck A S | $2,032.77 | 04/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251769175 |
| Principal investigator 1 | H. Lundbeck A S | $350.00 | 04/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251769212 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,051.30 | 04/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184180848 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 04/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184180868 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $230.85 | 04/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184180910 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.31 | 04/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184180912 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,080.00 | 04/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184180914 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $283.50 | 04/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184180936 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $570.00 | 04/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184180938 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,362.50 | 04/01/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184180940 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,847.69 | 03/25/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184178892 |
| Principal investigator 1 | ModernaTX, Inc. | $7,659.69 | 03/24/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991908 |
| Principal investigator 1 | ModernaTX, Inc. | $24,628.86 | 03/24/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991930 |
| Principal investigator 1 | ModernaTX, Inc. | $37,787.05 | 03/24/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991980 |
| Principal investigator 1 | BioNTech SE | $693.00 | 03/19/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021785 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,695.38 | 03/19/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184174620 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 03/19/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184174626 |
| Principal investigator 1 | ABBVIE INC. | $267.30 | 03/11/2025 | Non-covered Recipient Entity ACCELLACARE US INC | M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202462418 |
| Principal investigator 1 | ABBVIE INC. | $534.60 | 03/11/2025 | Non-covered Recipient Entity ACCELLACARE US INC | M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202462423 |
| Principal investigator 1 | BioNTech SE | $3,465.00 | 03/11/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021783 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,921.08 | 03/11/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184170922 |
| Principal investigator 1 | Eli Lilly and Company | $21.78 | 03/06/2025 | Non-covered Recipient Entity TRIANGLE MEDICAL RESEARCH ASSOCIATES LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187893768 |
| Principal investigator 1 | BioNTech SE | $90.42 | 03/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021803 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,130.22 | 03/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184156780 |
| Principal investigator 1 | ModernaTX, Inc. | $8,541.24 | 02/27/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991890 |
| Principal investigator 1 | ModernaTX, Inc. | $27,841.32 | 02/27/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991892 |
| Principal investigator 1 | ModernaTX, Inc. | $832.02 | 02/27/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991924 |
| Principal investigator 1 | ModernaTX, Inc. | $5,718.82 | 02/27/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991932 |
| Principal investigator 1 | ModernaTX, Inc. | $24,367.35 | 02/27/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991952 |
| Principal investigator 1 | ModernaTX, Inc. | $1,577.61 | 02/27/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991962 |
| Principal investigator 1 | ModernaTX, Inc. | $71,766.20 | 02/27/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991976 |
| Principal investigator 1 | ModernaTX, Inc. | $2,521.57 | 02/27/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991978 |
| Principal investigator 1 | ModernaTX, Inc. | $74.61 | 02/27/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252992004 |
| Principal investigator 1 | H. Lundbeck A S | $100.00 | 02/25/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251767728 |
| Principal investigator 1 | H. Lundbeck A S | $53.00 | 02/25/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251767739 |
| Principal investigator 1 | H. Lundbeck A S | $700.00 | 02/25/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251767758 |
| Principal investigator 1 | ModernaTX, Inc. | $1,342.98 | 02/24/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991942 |
| Principal investigator 1 | ModernaTX, Inc. | $149.22 | 02/21/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991922 |
| Principal investigator 1 | H. Lundbeck A S | $6,621.00 | 02/18/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251767429 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,774.25 | 02/18/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184154152 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,506.60 | 02/18/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184154154 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $189.00 | 02/18/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184154156 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $456.00 | 02/18/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184154158 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25,254.32 | 02/18/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184154472 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $342.00 | 02/18/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184154560 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,290.60 | 02/18/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184154570 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $189.00 | 02/18/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184154574 |
| Principal investigator 1 | PFIZER INC. | $36,574.78 | 02/06/2025 | Non-covered Recipient Entity Accellacare Us Inc | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1228831888 |
| Principal investigator 1 | H. Lundbeck A S | $18,255.00 | 02/05/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251766995 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,083.94 | 02/05/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184152492 |
| Principal investigator 1 | Eli Lilly and Company | $430.00 | 01/31/2025 | Non-covered Recipient Entity RHEUMATOLOGY CENTER OF HOUSTON | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | No dispute reported | 06/30/2026 | 1187887696 |
| Principal investigator 1 | ModernaTX, Inc. | $43.89 | 01/30/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991926 |
| Principal investigator 1 | H. Lundbeck A S | $20,440.00 | 01/29/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251766789 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,847.69 | 01/29/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184149842 |
| Principal investigator 1 | Eli Lilly and Company | $8,753.80 | 01/27/2025 | Non-covered Recipient Entity RHEUMATOLOGY CENTER OF HOUSTON | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187889538 |
| Principal investigator 1 | ModernaTX, Inc. | $12,360.25 | 01/27/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991900 |
| Principal investigator 1 | ModernaTX, Inc. | $39,620.34 | 01/27/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991936 |
| Principal investigator 1 | ModernaTX, Inc. | $4,426.21 | 01/27/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991940 |
| Principal investigator 1 | ModernaTX, Inc. | $3,800.46 | 01/27/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991944 |
| Principal investigator 1 | ModernaTX, Inc. | $61,979.90 | 01/27/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991984 |
| Principal investigator 1 | ModernaTX, Inc. | $5,043.14 | 01/27/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991998 |
| Principal investigator 1 | ModernaTX, Inc. | $3,155.22 | 01/27/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252992000 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $11,815.15 | 01/24/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192165103 |
| Principal investigator 1 | Eli Lilly and Company | $139,407.00 | 01/21/2025 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | No dispute reported | 06/30/2026 | 1187888952 |
| Principal investigator 1 | Eli Lilly and Company | $95,887.00 | 01/21/2025 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187889102 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $15,155.91 | 01/21/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184149038 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,918.94 | 01/17/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184148069 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,500.20 | 01/15/2025 | Non-covered Recipient Entity PMG RESEARCH OF RALEIGH | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190308048 |
| Principal investigator 1 | BioNTech SE | $4,706.16 | 01/14/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021777 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $26,897.00 | 01/14/2025 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH LLC PMG RESEARCH INC | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190298515 |
| Principal investigator 1 | BioNTech SE | $1,181.00 | 01/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021773 |
| Principal investigator 1 | BioNTech SE | $153.44 | 01/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021787 |
| Principal investigator 1 | BioNTech SE | $912.42 | 01/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021789 |
| Principal investigator 1 | BioNTech SE | $110.97 | 01/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021791 |
| Principal investigator 1 | BioNTech SE | $150.70 | 01/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021793 |
| Principal investigator 1 | BioNTech SE | $271.26 | 01/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021795 |
| Principal investigator 1 | BioNTech SE | $576.00 | 01/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021797 |
| Principal investigator 1 | BioNTech SE | $396.00 | 01/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021799 |
| Principal investigator 1 | BioNTech SE | $192.00 | 01/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | BNT163-01 | No dispute reported | 06/30/2026 | 1249021801 |
| Principal investigator 1 | Eli Lilly and Company | $430,549.00 | 01/07/2025 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187888956 |
| Principal investigator 1 | H. Lundbeck A S | $682.00 | 01/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251766302 |
| Principal investigator 1 | H. Lundbeck A S | $115.00 | 01/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS | No dispute reported | 06/30/2026 | 1251766323 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $23,742.45 | 01/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184146192 |
| Principal investigator 1 | ModernaTX, Inc. | $81.96 | 01/06/2025 | Non-covered Recipient Entity ACCELLACARE-RALEIGH | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252991992 |